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IMPORTANCE It is uncertain to what extent established cardiovascular risk factors are
associated with venous thromboembolism (VTE).
OBJECTIVE To estimate the associations of major cardiovascular risk factors with VTE, ie,
deep vein thrombosis and pulmonary embolism.
DESIGN, SETTING, AND PARTICIPANTS This study included individual participant data
mostly from essentially population-based cohort studies from the Emerging Risk Factors
Collaboration (ERFC; 731 728 participants; 75 cohorts; years of baseline surveys, February
1960 to June 2008; latest date of follow-up, December 2015) and the UK Biobank (421 537
participants; years of baseline surveys, March 2006 to September 2010; latest date of
follow-up, February 2016). Participants without cardiovascular disease at baseline were
included. Data were analyzed from June 2017 to September 2018.
EXPOSURES A panel of several established cardiovascular risk factors.
MAIN OUTCOMES ANDMEASURES Hazard ratios (HRs) per 1-SD higher usual risk factor levels (or
presence/absence). Incident fatal outcomes in ERFC (VTE, 1041; coronary heart disease [CHD],
25 131) and incident fatal/nonfatal outcomes in UKBiobank (VTE, 2321; CHD, 3385). Hazard
ratios were adjusted for age, sex, smoking status, diabetes, and bodymass index (BMI).
RESULTS Of the 731 728participants from theERFC, 403396 (55.1%)were female, and themean
(SD) age at the timeof the surveywas51.9 (9.0) years; of the421 537participants fromtheUK
Biobank, 233699 (55.4%)were female, and themean (SD) age at the timeof the surveywas 56.4
(8.1) years. Risk factors forVTE includedolder age (ERFC:HRperdecade, 2.67; 95%CI, 2.45-2.91;
UKBiobank:HR, 1.81; 95%CI, 1.71-1.92), current smoking (ERFC:HR, 1.38;95%CI, 1.20-1.58;UK
Biobank:HR,1.23;95%CI,1.08-1.40),andBMI(ERFC:HRper1-SDhigherBMI,1.43;95%CI,1.35-1.50;
UKBiobank:HR, 1.37; 95%CI, 1.32-1.41). For these factors, therewere similarHRs for pulmonary
embolismanddeepveinthrombosis inUKBiobank(exceptadipositywasmorestronglyassociated
withpulmonaryembolism)andsimilarHRsforunprovokedvsprovokedVTE.Apart fromadiposity,
these risk factorswere less strongly associatedwithVTE thanCHD.Therewere inconsistent
associationsofVTEswithdiabetes andbloodpressure acrossERFCandUKBiobank, and there
was limited ability to study lipid and inflammationmarkers.
CONCLUSIONS AND RELEVANCE Older age, smoking, and adiposity were consistently
associated with higher VTE risk.
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V enous thromboembolism(VTE), consistingofdeepveinthrombosis (DVT)orpulmonaryembolism(PE), is ama-jor clinical burden. Globally, there are about 10million
cases every year, and it is the third leading vascular disease af-
ter myocardial infarction and stroke.1 Pulmonary embolism is
amanifestationofVTEand is responsible formostVTEdeaths.2
In recent years, efforts to prevent VTE have broadened from
focusingmainly onhospital-based risk factors (eg, recent prior
surgery, cancer, and congestive heart failure) toward adoption
of heart-healthy lifestyles.3 This perspective has challenged
traditional views of venous and arterial thrombosis as distinct
pathologies, encouraging prevention strategies that concomi-
tantly address VTE and arterial thrombosis.2,4 However, there
is uncertainty about the extent to which venous and arterial
thrombosis share cardiovascular risk factors, as studies have
reported conflicting findings.5-15 Interpretation has been com-
plicated by the use of retrospective case-control designs, lim-
ited statistical power, and/or inability to compare VTE and
arterial disease outcomes within the same cohorts.16-26
Analyzing data frommore than 1.1 million participants in
76 prospective studies, we investigated associations of sev-
eral established cardiovascular risk factors with the inci-
denceofVTEoutcomes.Weaimed toaddress2principal ques-
tions: What are the associations of major cardiovascular risk
factorswithVTEoutcomes (includingsubtypes)?Howdothese
associations compare with those for coronary heart disease
(CHD), a manifestation of arterial thrombotic disease?
Methods
Data Sources and Participant Inclusion
We analyzed data from the Emerging Risk Factors Collabora-
tion (ERFC), a consortium of prospective cohort studies with
information on a variety of risk factors, and the UK Biobank,
a single large prospective study. Both the ERFC and UK
Biobankhavebeendescribedpreviously.27,28Bothdatasources
involve a prospective cohort study design and accessible
individual participant data, enabling standardized and de-
tailed analyses using a common protocol, including defini-
tions forVTEandCHDoutcomes.However,weconductedpar-
allel (rather than pooled) analyses of the 2 sources because of
potentially important differences in their approaches to VTE
ascertainment, ie, the ERFC recorded only fatal VTE out-
comeswhileUKBiobank recordedboth fatal andnonfatalVTE
outcomes, most of which were nonfatal. Information about
each of the 76 studies contributing to this analysis is pro-
vided in the eAppendix in the Supplement. The study was
designed and conducted by the Emerging Risk Factors
Collaboration academic coordinating center, and it was ap-
proved by the Cambridgeshire Ethics Review Committee.
Informed consent was obtained from participants in each of
the cohorts contributing to the analysis.
Participants in the contributing studies were eligible for
inclusion in the current analysis if theymet all of the following
criteria: (1) had recorded information on several established
cardiovascular risk factors (as aminimum, informationonage,
sex, smoking status, history of diabetes, and bodymass index
[BMI]), (2) did not have a knownbaseline history of cardiovas-
culardisease (CVD;definedasCHD,otherheartdisease, stroke,
transient ischemic attack, peripheral vascular disease, or
cardiovascular surgery) or VTE (defined as DVT or PE), and
(3) had at least 1 year of follow-up data after baseline.
In the ERFC, only fatal VTE events were recorded. Ascer-
tainmentwas based ondeath certificates supplemented in 56
studies by medical records, findings on autopsy, and other
sources. In UK Biobank, fatal and nonfatal VTEs were ascer-
tained through linkage with routinely collected medical rec-
ords. We attempted to subcategorize VTEs as provoked and
unprovoked using a pragmatic approach that required infer-
ence from routine records (eAppendix in the Supplement).
Briefly, following the example of previouswork,13wedefined
VTE as provoked if, in the 90-day period preceding the VTE,
the participantwas recorded as having amalignant neoplasm
(per cancer registry data); starting or ending a hospital epi-
sode with a main diagnosis code relating to malignant neo-
plasm, heart failure, infectious disease, or trauma; or having
a hospital episode that included certain types of surgical pro-
cedures. The specific International Statistical Classification
of Diseases and Related Health Problems (ICD) codes and
Classificationof InterventionsandProcedures codes that are in-
cluded in our definition are summarized in the eAppendix in
the Supplement. All studies useddefinitions of CHDbasedon
World Health Organization (or similar) criteria. In registering
fatal outcomes, the contributing studies classified deaths
according to the primary cause (or, in its absence, the under-
lying cause) on the basis of ICD-8, ICD-9, and ICD-10 codes to
at least 3 digits or according to study-specific classification
systems. In the ERFC, baseline surveys were given between
February 1960 and June 2008, and the date of latest
follow-upwas December 2015 (median, 2014 across studies);
in the UK Biobank, baseline surveys were given between
March 2006 and September 2010, and the date of latest
follow-up was February 2016.
Statistical Analysis
For continuous risk factors,we calculated hazard ratios (HRs)
per 1-SD higher usual risk factor level. For binary risk factors,
we compared presence vs absence of the factor. Cox propor-
tional hazards regressionmodelswere adjusted for age, smok-
ing status, historyofdiabetes, andBMIandstratifiedby study,
sex, and (when appropriate) trial arm. To avoid overadjust-
ment, we did not routinely adjust for systolic blood pressure
Key Points
Question To what extent are established cardiovascular risk
factors associated with risk of venous thromboembolism (VTE)?
Findings In this analysis of individual participant data from the
Emerging Risk Factors Collaboration and the UK Biobank including
1.1 million participants, among a panel of several established
cardiovascular risk factors, older age, smoking, and greater
adiposity were consistently associated with higher VTE risk.
Meaning There is overlap in at least someof themajor population
determinants of important venous andarterial thrombotic diseases.
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or lipid measurements (which, for example, can mediate the
effects of adiposity). Similarly,wedidnot adjust forBMIwhen
analyzing other measures of adiposity (eg, waist circumfer-
ence). Participants in the UK Biobank were censored at first
nonfatal CVD event, death, or study exit, whichever occurred
first. Participants inERFCwerecensoredatdeathor studyexit.
BecausenonfatalCVDmayresult inhospitalization(whichmay,
in turn, lead to VTE outcomes), sensitivity analyses addition-
ally censored at the first nonfatal CVD event in ERFC.
To correct for regression dilution caused by variability in
levels of continuous risk factors, we regressed serial measure-
ments of risk factors obtained from up to 146749 participants
in ERFC (mean interval, 8.4 years) and up to 24235 partici-
pants in UK Biobank (mean interval, 5.2 years) on baseline
levels of the relevant characteristics. Correction for within-
person variation in risk factors was achieved by use of condi-
tional expectations of long-term average levels (termed usual
levels) of the risk factors, which were predicted from regres-
sion calibration models and used in estimation of HRs, as
described previously.29
To characterize shapes of associations, HRs calculated
within overall fifths of baseline exposure values were plotted
againstmeanusualvaluesof therelevant risk factorwithineach
fifth. We used the Plummermethod to estimate 95% CIs from
the variances that corresponded to the amount of information
underlying each group (including the reference category).30
Because a further aim of the study was to compare asso-
ciations of risk factors with VTE vs CHD outcomeswithin the
same cohorts,we defined a competing riskmodel using a rec-
ord duplication approach, allowing for simultaneous cause-
specific hazard regression to estimate cause-specific HRs for
each type of event. In ERFC, we stratified the cause-specific
regressionmodelbycohort toallowforadifferentbaselinehaz-
ard function in each study. We tested for differences in asso-
ciations with VTE vs CHD based on the interaction between
eachexposurevariable and theevent type indicator variable.31
Analyses were carried out in Stata version 13 (StataCorp).
Because of the number of statistical tests done, principal
emphasis was given to findings with a P value less than .001,
and all P values were 2-sided.
Results
Data were available for 731 728 participants from 75 ERFC co-
hortsand421537participants fromUKBiobank(Table) (eTable1
in the Supplement). The mean (SD) age at baseline was 51.9
(9.0) years inERFCand56.4 (8.1) years inUKBiobank; 403396
participants (55.1%) in the ERFC and 233699 (55.4%) in UK
Biobankwere female.Mostparticipants inERFCwereenrolled
in either Europe (369757 of 731 728 [50.5%]) orNorthAmerica
(315278 of 731 728 [43.1%]). During amedian follow-up of 15.4
years, 1041 fatal VTE events and 25 131 fatal CHD events were
recorded in theERFC. InUKBiobank,2321 fatalornonfatalVTE
events and 3385 fatal or nonfatal CHD events were recorded
during amedian follow-up of 6.1 years.
Associationsof several risk factorswithVTEwereapproxi-
mately log-linear (Figure1).Olderagewasassociatedwithhigher
risk of VTE,with an approximately 2.8-fold higher risk per de-
cade inERFCand1.8-foldhigher riskperdecade inUKBiobank
(Figure2).Comparedwithfemales,maleshadahigherriskofVTE
inUKBiobank (HR, 1.44;95%CI, 1.32-1.56), somewhat less so in
ERFC(HR, 1.17;95%CI,0.998-1.38).Current smokingwasasso-
ciatedwith VTE risk in ERFC (HR, 1.38; 95% CI, 1.20-1.58), but
somewhat less so in UK Biobank (HR, 1.23; 95% CI, 1.08-1.40).
Markersofadiposity (BMI,waist-to-hip ratio, andwaist circum-
ference)werepositivelyassociatedwithhigherVTErisk inboth
ERFC and UK Biobank. For example, HRs per 1-SD higher BMI
were 1.43 (95%CI, 1.35-1.50) inERFCand1.37 (95%CI, 1.32-1.41)
inUKBiobank. Current alcohol consumptionwas inversely as-
sociatedwithVTErisk inbothERFC(HR,0.75;95%CI,0.61-0.93)
and UK Biobank (HR, 0.82; 95% CI, 0.71-0.94). In exploratory
analyses restricted to current drinkers in UK Biobank (which
should limit theeffectsofcertainresidualbiases, suchasreverse
causality related to sick quitters32), we found that the inverse
associationbetweenamountofalcohol consumedandVTErisk
persisted (eFigure 1 in the Supplement).
By contrast, for some other risk factors we studied, we
notedpotentially directionally discordant associations across
ERFCandUKBiobank.For example, 1-SDhigher systolic blood
pressurewasnotassociatedwith riskofVTE inERFC (HR, 1.07;
95%CI,0.95-1.19)butwas inverselyassociatedwith riskofVTE
inUKBiobank (HR,0.83; 95%CI, 0.77-0.90). Conversely, 1-SD
higherdiastolic bloodpressurewasassociatedwithhigher risk
of VTE in ERFC (HR, 1.26; 95% CI, 1.11-1.42) but was not asso-
ciatedwith risk ofVTE inUKBiobank (HR,0.94; 95%CI, 0.87-
1.02). In ERFC, history of diabeteswas associatedwith higher
riskofVTE (HR, 1.69;95%CI, 1.33-2.16) aswas 1-SDhigher fast-
ing baseline glucose concentration (HR, 1.27; 95% CI, 1.08-
1.48), while in UK Biobank, history of diabetes was inversely
associated with risk of VTE (HR, 0.83; 95% CI, 0.69-0.99). To
investigate whether these discordant associations chiefly
reflectedthedifferentVTEoutcomesrecordedacrossERFCand
UK Biobank, we restricted analysis to the UK Biobank (which
had recorded both fatal and nonfatal VTE outcomes). In UK
Biobank–specific analyses, we found a similar pattern of dif-
ference of HRs for fatal vs nonfatal VTEs with blood pressure
and diabetes to that observed in our comparison across ERFC
and UK Biobank (eFigure 2 in the Supplement). This result
suggests that blood pressure and diabetesmay have differing
associations with fatal vs nonfatal VTEs.
At the timeofouranalysis,dataonplasmabiomarkerswere
available in the ERFC but not in UK Biobank (Figure 2). In the
ERFC,apolipoproteinB,apolipoproteinA,andlipoprotein(a) lev-
els each showed suggestively inverse associations with risk of
VTE, whereas triglyceride, non–high-density lipoprotein cho-
lesterol, and high-density lipoprotein cholesterol levels each
showednoassociations.Fastingglucose,C-reactiveprotein,and
fibrinogen levelswere each associatedwithhigher risk ofVTE.
In analyses comparing PE with DVT, higher BMI and
higher waist circumference had stronger associations with
PE than DVT (Figure 3). Further analyses that subcategorized
VTE outcomes as provoked vs unprovoked in UK Biobank
did not reveal major differences in the associations of most
CVD risk factors, with the exceptions of older age and male
sex (Figure 4).
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InanalysescomparingVTEwithCHDoutcomes,associations
werestrongerforCHDinbothERFCandUKBiobankformostrisk
factors, includingage,malesex, currentsmokingstatus,history
ofdiabetes,highersystolicanddiastolicbloodpressure,andpro-
atherogenic lipid levels (eFigures3and4 in theSupplement). In
contrast, higher BMI and waist circumference had somewhat
strongerassociationswithVTEcomparedwithCHD,whereascir-
culating inflammatorymarkerswere associatedwithboth con-
ditionstoabroadlysimilarextent(eFigures3and4intheSupple-
ment).Findingswerebroadlysimilar insensitivityanalyses that
didnotadjustforBMI(eTable2intheSupplement),excludedpar-
ticipantswith history of cancer diagnosis at baseline (eFigure 5
intheSupplement), censoredfor firstCVDevents inERFC(eFig-
ure6intheSupplement),andusedbaseline levelsof riskfactors,
except for the expected decrease in themagnitudes of associa-
tionwhennotcorrectingforwithin-personvariability inthecon-
tinuous variables (eFigures 7-9 in the Supplement).
Discussion
In this analysis of individual-level data on several estab-
lished cardiovascular risk factors from more than 1.1 million
participants in 76 cohorts, we found that older age, smoking,
Table. Summary of Baseline Characteristics and Outcomes Recorded
Characteristic
ERFC UK Biobanka
No. of
Cohorts No. Measure No. Measure
Demographic and lifestyle factors, No. (%)
Age at baseline survey, mean (SD), y 75 731 728 51.9 (9.0) 421 537 56.4 (8.1)
Male 70 731 728 328 332 (44.9) 421 537 187 838 (44.6)
Current smoker 75 731 728 222 016 (30.3) 421 537 43 847 (10.4)
History of diabetes 74 731 728 25 982 (3.6) 421 537 17 622 (4.2)
Current alcohol drinker 58 386 831 271 499 (70.2) 421 197 389 507 (92.5)
Anthropometric and physical markers,
mean (SD)
Systolic blood pressure, mm Hg 73 566 724 131 (19) 421 179 137 (19)
Diastolic blood pressure, mm Hg 72 565 895 80.0 (10.9) 421 181 82.2 (10.1)
Body mass indexb 75 731 728 25.4 (4.2) 421 537 27.2 (4.7)
Waist-to-hip ratio 34 264 787 0.85 (0.08) 421 440 0.87 (0.09)
Waist circumference, cm 36 265 465 87.6 (12.5) 421 464 89.6 (13.2)
Lipid-related markers, mean (SD)
Total cholesterol levels, mg/dL 68 455 177 222.0 (43.6) NA NA
Non-HDL cholesterol levels, mg/dL 57 311 888 171.0 (44.8) NA NA
HDL cholesterol levels, mg/dL 57 312 207 52.9 (14.7) NA NA
Log triglyceride levels, mg/dLc 56 322 096 4.79 (0.53) NA NA
Apolipoprotein B levels, mg/dL 20 80 712 103 (29) NA NA
Apolipoprotein A1 levels, mg/dL 20 84 483 137 (33) NA NA
Log Lp(a) levels, mg/dLd 18 66 382 2.20 (1.20) NA NA
Metabolic and inflammatory markers,
mean (SD)
Fasting glucose levels, mg/dL 33 130 322 88.5 (24.3) NA NA
Log CRP levels, mg/Le 28 70 855 0.46 (1.07) NA NA
Fibrinogen levels, mg/dL 29 115 002 241.2 (68.7) NA NA
Albumin levels, g/dL 25 115 309 4.29 (0.39) NA NA
Study period, median
(5th centile-95th centile)f
Baseline survey year 75 731 728 1986
(1971-2000)
421 537 2009
(2007-2010)
Latest follow-up year 75 731 728 2004
(1989-2011)
421 537 2016
(2016-2016)
Outcomes, No.
Time to event or censoring, median
(5th centile-95th centile), y
75 731 728 15.4
(5.5-32.0)
421 537 6.1
(4.8-7.5)
Total follow up, person-years in millions 75 731 728 12.807 421 537 2.566
Non-fatal MI NAg NA NA 421 537 2808
Fatal CHD 75 731 728 25 131 421 537 577
VTE 75 731 728 1041 421 537 2321
Nonfatal VTE NAg NA NA 421 537 2234
Fatal VTE 75 731 728 1041 421 537 87
Pulmonary embolism 75 731 728 855 421 537 1273
Deep venous thromboembolism 75 731 728 186 421 537 1048
Unprovoked VTE NA NA NA 421 537 1465
Provoked VTE NA NA NA 421 537 856
Abbreviations: CHD, coronary heart
disease; CRP, C-reactive protein;
ERFC, Emerging Risk Factors
Collaboration; HDL, high-density
lipoprotein; Lp(a), lipoprotein(a);
MI, myocardial infarction; NA, not
applicable; PE, pulmonary embolism;
VTE, venous thromboembolism.
SI conversion factor: To convert
cholesterol to millimoles per liter,
multiply by 0.0259; triglycerides to
millimoles per liter, multiply by
0.0113; apolipoprotein to grams per
liter, multiply by 0.01; Lp(a) to
micromoles per liter, multiply by
0.0357; fasting glucose to
micromoles per liter, multiply by
0.0555; CRP to nanomoles per liter,
multiply by 9.524; fibrinogen to
grams per liter, multiply by 0.01; and
albumin to grams per liter, multiply
by 10.
a At the time of these analyses, data
on plasma biomarkers were not
available in UK Biobank.
bBodymass index calculated as
weight in kilograms divided by
height in meters squared.
c Median (interquartile range)
triglyceride level was
117 (82-170) mg/dL.
dMedian (interquartile range) Lp(a)
level was 9 (4-25) mg/dL.
e Median (interquartile range) CRP
level was 1.48 (0.72-3.15) mg/dL.
f Follow-up and outcome summaries
among participants with complete
data on age, sex, smoking status,
history of diabetes, and body
mass index.
gMost of the studies in ERFC did not
ascertain nonfatal VTE outcomes;
hence, analyses in ERFCwere
restricted to comparison of fatal
CHD outcomes only.
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and higher levels of adiposity were clearly associated with
higher risk of VTE. These findings suggest that there is over-
lap in at least somemajor population determinants of impor-
tant venous and arterial thrombotic diseases.
Our study characterized dose-response associations be-
tweenseveral clinicalmeasuresof adiposity (eg,waist circum-
ference and BMI) and VTE risk and showed no evidence of a
threshold below which leaner body habitus stopped being
associatedwith lowerVTErisk.Theassociationofobesitywith
VTE is supportedbypreviousmendelian randomization stud-
ies of genetic variants associated with increased adiposity,
which are also associatedwith increased risk ofVTE.33,34 Fur-
thermore, we found that associations of BMI and waist cir-
cumferenceweresomewhatstrongerwithPEvsDVTandabout
twice as strong with VTE vs CHD. These data suggest that
efforts to combat the entire spectrum of obesity and over-
weight should yield important benefits for VTE prevention.
As regards risk behaviors, our study confirmed theknown
association of current smokingwith risk of VTE.9,13 This asso-
ciationwas similar inmagnitude forPEandDVToutcomesbut
weaker than that observed for CHD. Previous studies have
suggested thatmuch of the excess risk of VTE in smokerswas
because of increased hospitalization for smoking-related
diseases, includingcancer.35,36However, inouranalysis, smok-
ing was similarly associated with both provoked and unpro-
voked VTE; furthermore, HRs did not change appreciably
after exclusion of participants with history of cancer diagno-
sis at baseline. We also noted a pattern of association
Figure 1. Hazard Ratios (HRs) for Venous Thromboembolism (VTE) by 10-Year Age Groups and Fifths of Continuous Factors
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All comparisons were adjusted for age, sex, smoking status, history of diabetes,
and usual bodymass index (BMI; calculated as weight in kilograms divided by
height in meters squared) (waist-to-hip ratio and waist circumference were not
adjusted for usual BMI). The reference category is age 50 to 59 years for age
and is the bottom fifth for all other continuous variables. Associations involve
Emerging Risk Factors Collaboration (ERFC) data for fatal VTE and UK Biobank
data for VTE. Data on cholesterol and triglyceride levels were unavailable in UK
Biobank at the time of analysis. Most UK Biobank participants were aged
between 40 and 69 years at baseline. The dotted line indicates the reference
value. HDL indicates high-density lipoprotein.
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between alcohol consumption and VTE similar to that re-
ported in previous studies of alcohol consumption and
nonfatalmyocardial infarction.32,37,38 (Bycontrast, alcoholcon-
sumptionhaspreviously beenpositively associatedwith risks
of fatal coronary disease, stroke, and heart failure.) Although
previous studies have reported that moderate alcohol con-
sumption is associated with lower levels of hemostatic fac-
tors (eg, fibrinogen, factorVII, andvonWillebrand factor),39,40
further studies are needed to determine whether moderate
alcohol consumption has a causal role in VTE.
Our study identified potentially inverse associations of
proatherogenic lipid levels with VTE. For example, apolipo-
Figure 2. Hazard Ratios (HRs) for Venous Thromboembolism (VTE) for Established Cardiovascular Risk Factors
HR (95% CI) per 1-SD Higher
or Contrasta
1 2 40.5
Risk Factor No.
No. of
Events
HR
(95% CI)
Association
P Value
Age (per decade)
UK Biobank
ERFC
421 537
731 728
2321
1041
1.81 (1.71-1.92)
2.67 (2.45-2.91)
<.001
<.001
Sex (male vs female)
UK Biobank
ERFC
421 537
731 728
2321
1041
1.44 (1.32-1.56)
1.17 (0.998-1.38)
<.001
.053
Smoking (current vs other)
UK Biobank
ERFC
421 537
731 728
2321
1041
1.23 (1.08-1.40)
1.38 (1.20-1.58)
.002
<.001
Diabetes (yes vs no)
UK Biobank
ERFC
421 537
731 728
2321
1041
0.83 (0.69-0.99)
1.69 (1.33-2.16)
.04
<.001
Alcohol consumption (current vs other)
UK Biobank
ERFC
421 197
386 831
2319
564
0.82 (0.71-0.94)
0.75 (0.61-0.93)
.006
.01
Systolic blood pressure
UK Biobank
ERFC
421 179
566 724
2315
887
0.83 (0.77-0.90)
1.07 (0.95-1.19)
<.001
.28
Diastolic blood pressure
UK Biobank
ERFC
421 181
565 895
2315
885
0.94 (0.87-1.02)
1.26 (1.11-1.42)
.15
<.001
BMI
UK Biobank
ERFC
421 537
731 728
2321
1041
1.37 (1.32-1.41)
1.43 (1.35-1.50)
<.001
<.001
Waist-to-hip ratio
UK Biobank
ERFC
421 440
264 787
2319
329
1.52 (1.40-1.65)
1.23 (1.05-1.45)
<.001
.01
Waist circumference
UK Biobank
ERFC
421 464
265 465
2320
333
1.60 (1.52-1.68)
1.54 (1.37-1.73)
<.001
<.001
Non-HDL cholesterol levels
ERFC 311 888 440 0.88 (0.76-1.03) .11
HDL cholesterol levels
ERFC 312 207 440 1.09 (0.94-1.26) .27
Log triglycerides levels
ERFC 322096 537 0.95 (0.81-1.11) .49
Apolipoprotein B levels
ERFC 80 712 261 0.76 (0.61-0.94) .01
Apolipoprotein A1 levels
ERFC 84 483 265 0.65 (0.47-0.88) .006
Log Lp(a)
ERFC 66 382 210 0.83 (0.71-0.98) .03
Fasting glucose levels
ERFC 130 322 323 1.27 (1.08-1.48) .003
Log CRP
ERFC 70 855 231 1.71 (1.33-2.20) <.001
Fibrinogen levels
ERFC 115 002 223 1.37 (1.11-1.68) .003
Albumin levels
ERFC 115 309 367 0.75 (0.56-1.02) .07
All comparisons were adjusted for
age, sex, smoking status, history of
diabetes, and usual bodymass index
(BMI) (waist-to-hip ratio and waist
circumference were not adjusted for
usual BMI). Associations involve
Emerging Risk Factors Collaboration
(ERFC) data for fatal VTE and UK
Biobank data for VTE. CRP indicates
C-reactive protein; HDL, high-density
lipoprotein; Lp(a), lipoprotein(a).
a Hazard ratios are presented per 1-SD
higher usual risk factor level unless
otherwise indicated.
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protein B and lipoprotein(a) levels were each associated with
lower risk of VTE, a finding that awaits further elucidation.41
Proinflammatory soluble biomarkers (eg, C-reactive protein)
were positively associated with VTE, a finding consistent
with the associations we observed for CHD outcomes.
Although previous mendelian randomization studies sug-
gest that CRP and fibrinogen levels are unlikely to be direct
causal factors in CHD,42,43 such genetic epidemiological data
are sparser in relation to VTE.
It is not clear why our study found inconsistent associa-
tions of blood pressure and history of diabetes with VTE out-
comes across UK Biobank and the ERFC. One potential
explanation is that these data sources recorded mostly dif-
fering types of VTE outcomes, ie, UK Biobank involved
mostly nonfatal outcomes whereas ERFC involved only fatal
outcomes. Our exploratory analysis of UK Biobank data was
consistent with this explanation, as it found differing results
with blood pressure and diabetes for fatal VTE vs nonfatal
VTE similar to those observed in comparisons across UK
Biobank and the ERFC. However, future studies with more
detailed clinical information will be needed to understand
these possible differences with greater confidence.
Strengths and Limitations
Our study had major strengths. It avoided the limitations
of retrospective case-control study designs by analyzing
prospective cohort data on more than 1.1 mil l ion
participants without CVD at baseline. Access to individual
participant data avoided the limitations of literature-based
meta-analyses. It also enabled a common approach
to adjustment for potential confounding factors, time-to-
event analyses, correction for regression dilution bias,
and head-to-head comparisons of VTE and CHD. We
explored idiopathic VTE vs VTE provoked by established
risk factors (such as cancer or prolonged immobility),
albeit using pragmatic record-based definitions.44
The generalizability of our results was enhanced by
inclusion of data from 75 prospective studies in ERFC
recruited from 1960 through 2008 in 18 different
countries. To enhance power and evaluate the relevance
of findings to the contemporary situation, we included
data from UK Biobank, which recruited participants from
2006 to 2010.
Our study also had limitations. We did not routinely
have information in ERFC data on non-CVD risk factors
Figure 3. Hazard Ratios (HRs) for Pulmonary Embolism (PE) vs Deep Vein Thrombosis (DVT)
for Established Cardiovascular Risk Factors in UK Biobank
HR (95% CI) per 1-SD Higher
or Contrasta
1 2 40.5
Risk Factor No.
No. of
Events
HR
(95% CI)
Difference
P Value
Age (per decade)
PE
DVT
421 537
421 537
1273
1048
1.91 (1.76-2.06)
1.70 (1.57-1.85)
.051
Sex (male vs female)
PE
DVT
421 537
421 537
1273
1048
1.37 (1.23-1.54)
1.52 (1.34-1.72)
.24
Smoking (current vs other)
PE
DVT
421 537
421 537
1273
1048
1.29 (1.09-1.53)
1.16 (0.95-1.40)
.40
Diabetes (yes vs no)
PE
DVT
421 537
421 537
1273
1048
0.74 (0.57-0.95)
0.94 (0.72-1.23)
.20
Alcohol consumption (current vs other)
PE
DVT
421 197
421 197
1272
1047
0.90 (0.74-1.10)
0.73 (0.60-0.90)
.15
Systolic blood pressure
PE
DVT
421 179
421 179
1268
1047
0.78 (0.70-0.86)
0.91 (0.81-1.02)
.046
Diastolic blood pressure
PE
DVT
421 181
421 181
1268
1047
0.96 (0.86-1.07)
0.92 (0.81-1.04)
.60
BMI
PE
DVT
421 537
421 537
1273
1048
1.44 (1.38-1.50)
1.28 (1.21-1.35)
.001
Waist-to-hip ratio
PE
DVT
421 440
421 440
1272
1047
1.67 (1.50-1.85)
1.35 (1.20-1.53)
.01
Waist circumference
PE
DVT
421 464
421 464
1273
1047
1.74 (1.63-1.86)
1.43 (1.33-1.54)
<.001
All comparisons were adjusted for
age, sex, smoking status, history of
diabetes, and usual bodymass index
(BMI) (waist-to-hip ratio and waist
circumference were not adjusted for
usual BMI). Associations involve UK
Biobank data only.
a Hazard ratios are presented per 1-SD
higher usual risk factor level unless
otherwise indicated.
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for VTE (eg, oral contraception use) or medication use (eg,
anticoagulants). Misclassification of disease outcomes
could have arisen from inaccuracies in hospital discharge
records and death certificates, diluting the strength of the
observed associations.45-47 However, 2 observations argue
against major disease misclassification in our study.
First, we observed associations of measures of adiposity
with VTE risk similar in size to those previously reported in
much smaller studies based on detailed validation
of VTE events.6 Second, we observed directionally opposite
associations of proatherogenic lipid levels with VTE
and CHD outcomes despite the 2 conditions having similar
clinical presentations.
Conclusions
Amongapanelofseveralestablishedcardiovascular risk factors,
older age, smoking, and adipositywere consistently associated
with higher VTE risk. There is overlap in at least some of the
majorpopulationdeterminantsof importantvenousandarterial
thrombotic diseases.
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Figure 4. Hazard Ratios (HRs) for Unprovoked vs Provoked Venous Thromboembolism (VTE)
for Established Cardiovascular Risk Factors in UK Biobank
HR (95% CI) per 1-SD Higher
or Contrasta
1 2 40.5
Risk Factor No.
No. of
Events
HR
(95% CI)
Difference
P Value
Age (per decade)
Unprovoked VTE
Provoked VTE
421 537
421 537
1465
856
1.68 (1.57-1.80)
2.07 (1.88-2.28)
.001
Sex (male vs female)
Unprovoked VTE
Provoked VTE
421537
421 537
1465
856
1.62 (1.46-1.79)
1.18 (1.03-1.35)
<.001
Smoking (current vs other)
Unprovoked VTE
Provoked VTE
421 537
421 537
1465
856
1.23 (1.05-1.45)
1.22 (0.98-1.51)
.91
Diabetes (yes vs no)
Unprovoked VTE
Provoked VTE
421 537
421 537
1465
856
0.78 (0.62-0.99)
0.91 (0.68-1.22)
.44
Alcohol consumption (current vs other)
Unprovoked VTE
Provoked VTE
421 197
421 197
1465
854
0.83 (0.69-0.99)
0.81 (0.64-1.02)
.89
Systolic blood pressure
Unprovoked VTE
Provoked VTE
421 179
421 179
1460
855
0.86 (0.78-0.95)
0.79 (0.69-0.90)
.28
Diastolic blood pressure
Unprovoked VTE
Provoked VTE
421 181
421 181
1460
855
1.01 (0.91-1.12)
0.83 (0.73-0.95)
.02
BMI
Unprovoked VTE
Provoked VTE
421 537
421 537
1465
856
1.40 (1.34-1.46)
1.31 (1.24-1.39)
.08
Waist-to-hip ratio
Unprovoked VTE
Provoked VTE
421 440
421 440
1464
855
1.58 (1.43-1.75)
1.42 (1.24-1.63)
.21
Waist circumference
Unprovoked VTE
Provoked VTE
421 464
421 464
1465
855
1.67 (1.58-1.78)
1.47 (1.35-1.60)
.01
All comparisons were adjusted for
age, sex, smoking status, history of
diabetes, and usual bodymass index
(BMI) (waist-to-hip ratio and waist
circumference were not adjusted for
usual BMI). Associations involve UK
Biobank data only.
a Hazard ratios are presented per 1-SD
higher usual risk factor level unless
otherwise indicated.
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